Chlorhexidine Gluconate Dressing Market Size, Share, and Industry Analysis, By Product Type (CHG Transparent IV Securement Dressings, CHG Foam/Disc Dressings, CHG Gel Pads, and Others), By Application (Surgical Site Infection (SSIs), Catheter-Related Blood Stream Infections (CRBSI), Central Line-Associated Bloodstream Infections (CLABSI), and Others), By End-user (Hospitals & ASCs, Specialty Clinics, Dialysis Centers, and Others), and Regional Forecast till 2034

The global chlorhexidine gluconate dressing market was valued at USD 1.03 billion in 2025. The market is projected to grow from USD 1.08 billion in 2026 and reach a market valuation of USD 1.60 billion by 2034, exhibiting a CAGR of 5.0% during the forecast period.

The market growth is attributed to strong hospital focus on infection prevention protocols and rise in surgical procedures and critical care admissions. This is increasing the demand for CHG dressings for device securement and infection prevention.

Chlorhexidine Gluconate Dressing Market Driver

Rising Burden of Catheter-Related Infections to Drive the Market Growth

Over the past few years, there has been an increasing use of central venous catheters, PICC lines, dialysis catheters, and peripheral IV lines, which is contributing to a significant burden of catheter-related infections. In such a scenario, CHG dressings help reduce microbial growth around catheter insertion sites and lower the risk of catheter-related bloodstream infections, which is anticipated to boost their adoption and augment market growth.

• For instance, according to data published by the National Center for Biotechnology Information in January 2022, a study among 170 patients at the University Hospital Center (UHC) found an overall prevalence of CRBSI of 58.8%.

Download Free sample to learn more about this report.

According to the American Hospital Association's 2026 data, there are approximately 6,100 hospitals in the U.S.

Chlorhexidine Gluconate Dressing Market Restraint

Higher Cost Compared to Standard Dressings to Hamper the Market Growth

CHG dressings are more expensive than conventional transparent films, gauze, and basic securement dressings. This is expected to limit adoption in cost-sensitive hospitals, smaller clinics, and emerging markets. Moreover, procurement teams may prefer lower-cost alternatives when infection rates are already under control or budgets are limited. These factors are expected to hinder the market expansion.

Chlorhexidine Gluconate Dressing Market Opportunity

Expansion in Emerging Healthcare Markets to Offer Lucrative Growth Opportunities

In recent years, developing countries in Asia Pacific, Latin America, and parts of the Middle East have been improving hospital infrastructure, increasing surgical volumes, and focusing on infection prevention. As healthcare facilities modernize, the demand for advanced antimicrobial dressings is expected to increase, creating significant opportunities for CHG dressing suppliers.

• For instance, in February 2026, the India Brand Equity Foundation reported that India was introducing major reforms to strengthen its healthcare ecosystem, focusing on improved accessibility, affordability, and future preparedness.

Segmentation

Key Insights

The report covers the following key insights:

• Prevalence/Incidence of Key Conditions, by Key Countries/Region, 2025
• Key Industry Developments - (Partnerships, Mergers, Acquisitions, and Others)

Analysis by Product Type

By product type, the market is segmented into CHG transparent IV securement dressings, CHG foam/disc dressings, CHG gel pads, and others.

The CHG transparent IV securement dressings segment is expected to hold the major share of the global market during the forecast period. Hospitals are preferring these dressings as they allow clinicians to monitor the insertion site without removing the dressing, reducing unnecessary dressing changes and infection risk. This is expected to drive the segment growth during the forecast period.

Analysis by Application

By application, the market is segmented into surgical site infection (SSIs), catheter-related blood stream infections (CRBSI), central line-associated bloodstream infections (CLABSI), and others.

The catheter-related blood stream infections (CRBSI) segment is expected to hold the major share of the global chlorhexidine gluconate dressing market during the forecast period. The segment growth is attributed to the high clinical risk associated with vascular access devices. Patients with central lines, PICC lines, dialysis catheters, and long-term IV access are vulnerable to bloodstream infections, making antimicrobial protection essential and driving adoption of CHG dressings.

Analysis by End-user

Based on end-user, the market is divided into hospitals & ASCs, specialty clinics, dialysis centers, and others.

The hospitals & ASCs segment is expected to hold the largest share of the global market during the forecast period. Hospitals have strong infection-control protocols and larger procurement budgets, which support the higher adoption of CHG dressings. As a result, a higher number of hospitals worldwide is expected to support the segment growth in the forthcoming years.

• For instance, according to data from the International Trade Administration (ITA) in September 2025, China had over 40,000 hospitals in 2024.

Regional Analysis

Request for Customization   to gain extensive market insights.

Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for a 39.2% share of the global chlorhexidine gluconate dressing market in 2025. The regional growth is due to strong hospital infection-prevention protocols, high adoption of advanced IV securement products, and widespread use of central venous catheters, PICC lines, and dialysis catheters.

Asia Pacific is anticipated to expand at the fastest CAGR during the forecast period. The growth is driven by rising surgical procedures, growing dialysis and oncology patient pools, and increasing awareness of infection prevention in China, Japan, India, South Korea, and Australia.

• For instance, according to data published by the Smart Surgeons in July 2024, an estimated 30.0 million surgeries are performed each year in the U.S.

Key Players Covered

The global chlorhexidine gluconate dressing market is moderately consolidated, with a few global companies holding strong positions due to established hospital relationships, broad infection-prevention portfolios, and clinically recognized products.

The report includes the profiles of the following key players:

• Solventum (U.S.)
• BD (U.S.)
• Johnson & Johnson MedTech (U.S.)
• Datt Mediproducts (India)
• Avery Dennison Corporation (U.S.)
• Boen Healthcare Co., Ltd. (China)
• JCMED (China)
• Luck Medical Consumables Co., LIMITED (China)
• Medline Industries, LP (U.S.)
• Weifang Hota New Material Technology Co., LTD (China)

Key Industry Developments

• March 2022: Cardinal Health launched the first surgical incise drape using chlorhexidine gluconate (CHG) with Avery Dennison’s BeneHold CHG adhesive technology to help reduce surgical site contamination risk.
• February 2021: TIDI Products launched vascular access securement dressings with PrevaHexCHX antimicrobial protection, using chlorhexidine-based antimicrobial technology.